Gain Therapeutics (NASDAQ:GANX) Stock Price Up 0.8%

Shares of Gain Therapeutics, Inc. (NASDAQ:GANXGet Rating) rose 0.8% during trading on Thursday . The company traded as high as $3.95 and last traded at $3.90. Approximately 17,025 shares were traded during trading, a decline of 81% from the average daily volume of 90,065 shares. The stock had previously closed at $3.87.

Analyst Ratings Changes

Separately, B. Riley lowered Gain Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $11.00 to $5.00 in a research note on Friday, August 19th.

Gain Therapeutics Stock Up 0.8 %

The company has a quick ratio of 7.58, a current ratio of 7.58 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $3.85 and a 200 day simple moving average of $3.65. The stock has a market cap of $46.34 million, a price-to-earnings ratio of -2.89 and a beta of 0.07.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its position in shares of Gain Therapeutics by 373.5% during the first quarter. Royal Bank of Canada now owns 50,000 shares of the company’s stock valued at $205,000 after buying an additional 39,440 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Gain Therapeutics in the second quarter worth $119,000. Jane Street Group LLC purchased a new position in Gain Therapeutics in the first quarter worth $48,000. CM Management LLC boosted its position in Gain Therapeutics by 38.9% in the first quarter. CM Management LLC now owns 125,000 shares of the company’s stock worth $511,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Advisor Group Holdings Inc. purchased a new position in Gain Therapeutics in the fourth quarter worth $54,000. Hedge funds and other institutional investors own 9.05% of the company’s stock.

About Gain Therapeutics

(Get Rating)

Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

Read More

Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with's FREE daily email newsletter.